A phase I, randomized, proof ‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers

ConclusionsBI 409306 increased rapidly in plasma and was subsequently detected in CSF, resulting in dose‐dependent increases in cGMP levels in CSF. Results indicate BI 409306 efficiently crosses the blood‐CSF barrier, with an acceptable level of AEs.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhup.2569

Source: Human Psychopharmacology: Clinical and Experimental - January 24, 2017 Category: Psychiatry Authors: Katja Boland, Viktoria Moschetti, Chantaratsamon Dansirikul, Solen Pichereau, Lien Gheyle, Frank Runge, Heike Zimdahl ‐Gelling, Michael Sand Tags: RESEARCH ARTICLE Source Type: research